NRAS
NRAS mutations activate downstream signaling pathways involved in cancer progression. These alterations are common in melanoma and hematologic malignancies.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where NRAS is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Colorectal Cancer (CRC) Solid Tumor · Colorectal |
|
Approvals defined at the solid tumor level where NRAS is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report NRAS as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports NRAS as part of its biomarker panel.
Reports NRAS as part of its biomarker panel.
Reports NRAS as part of its biomarker panel.
Reports NRAS as part of its biomarker panel.